110841-71-9

Usage

Uses

Used in Pharmaceutical Applications:
4-Methyl-1,2,3,4-tetrahydroisoquinoline is used as a precursor for the synthesis of ABHD6 and dual ABHD6/MGL inhibitors. These inhibitors play a crucial role in modulating biological processes and have potential therapeutic applications in treating various diseases and conditions.
Used in Chemical Synthesis:
In the chemical industry, 4-methyl-1,2,3,4-tetrahydroisoquinoline can be utilized as a building block for the synthesis of more complex organic molecules. Its unique structure and functional groups make it a valuable intermediate in the development of novel compounds with diverse applications.
Used in Research and Development:
4-Methyl-1,2,3,4-tetrahydroisoquinoline is also employed in research and development settings, where it serves as a model compound for studying the properties and reactivity of isoquinoline derivatives. This helps researchers gain a deeper understanding of the structure-activity relationships and potential applications of related compounds.

Upstream product

• 4383-22-6 Allylbenzylamine 
• 70079-42-4 4-methyl-3,4-dihydro-2H-isoquinolin-1-one 
• 86457-01-4 4-methyl-3,4-dihydro-isoquinoline 
• 1532-97-4 4-bromoisoquinoline 
• 100-52-7 benzaldehyde 
• 111635-03-1 (2-phenyl-propyl)carbamic acid methyl ester 
• 582-22-9 2-phenylpropylamine 
• 1196-39-0 4-methylisoquinoline 

Downstream Products

• 70079-42-4 4-methyl-3,4-dihydro-2H-isoquinolin-1-one 
• 198883-95-3 N-benzoyl-4-methyl-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

Conformational Analysis. 50. C-Methyl-1,2,3,4-tetrahydroisoquinolines

Conformational equilibria in 1-, 3-, and 4-methyl-1,2,3,4-tetrahydroisoquinolines (THIQs) and the diastereomeric pairs of their 1,3- and 1,4-dimethyl homologs have been determined by measurement of H3/H4(trans) coupling constants and have been confirmed by molecular mechanics [MMP2(85)] calculations. The experimental -ΔG ° values (a → e) for the monomethyl compounds (computed values in parentheses) in kcal mol-1 are Me-1, 0.56 (0.46); Me-3, 1.63 (1.53); and Me-4, -0.32 (-0.22). Agreement of experimental and calculated values is very good as is the additivity of values for the dimethyl compounds (Table 1). Values for the corresponding hydrochlorides are Me-1, 0.19 (-0.34); Me-3, 1.15 (1.46); and Me-4, 0.35 (0.10) kcal mol-1. The less than satisfactory agreement of experimental with computed data here is probably due to neglect of solvation. The very small or negative ΔG ° values for Me-1 and Me-4 were ascribed not only to the pseudoaxial (rather than axial) nature of Me(ax) and the absence of a syn-axial hydrogen on the side of the benzene ring but also to a peri interaction with H(8) and H(5), respectively, destabilizing equatorial methyl at positions 1 and 4. This was confirmed by comparing computed conformational energy values with values at corresponding positions in Δ3,4-tetrahydropyridines (THPs). While ΔG ° in the two series is the same for Me-3 (THIQ numbering), that for Me-1 and Me-4 is considerably smaller in the THIQ than in the THP series which latter is devoid of peri hydrogens.

Conformational and steric aspects of the inhibition of phenylethanolamine N-methyltransferase by benzylamines

Compounds of the benzylamine (BA) class are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28). Restriction of the aminomethyl side chain through its incorporation into a cyclic framework as in 1,2,3,4-tetrahydroisoquinoline (

Reduction of isoquinoline and pyridine-containing heterocycles with lithium triethylborohydride (Super-Hydride)

Isoquinolines, quinoline and pyridines are effectively reduced to 1,2,3,4-tetrahydroisoquinolines, 1,2,3,4-tetrahydroquinolines and piperidines respectively with lithium triethylborohydride (Super-Hydride). The mechanism of the reduction was explored by reduction of isoquinoline and pyridine with lithium triethylborodeuteride (Super-Deuteride).

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic compounds as inhibitors of viral replication

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Tetrahydroisoquinoline derivative and medical preparation containing the same

The present invention relates to a tetrahydroisoquinoline derivative represented by the following formula 1 exhibiting an inhibitory action for agglutination caused by fibrinogen, which may be effectively used as an antithrombotic agent or a platelet agglutination-inhibiting agent. The present invention also relates to a medical preparation containing such compound. STR1 In formula 1, B and G are an alkylene optionally substituted with an alkyl or the like; D is H, an alkyl, or the like; E is 1,2,3,4-tetrahydroisoquinoline optionally substituted with R1 to R4 which binds to G at position 2; R1 to R4 are an alkyl or the like; L is hydroxy or the like; and A is a substituent represented by formula (2), and C is carbon. STR2 In formula 2, M and R5 to R8 are H, an alkyl or the like.